Published in J Clin Invest on October 01, 1961
Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. J Pharmacol Exp Ther (1960) 2.04
Stimulatory effect of barbital on urinary excretion of L-ascorbic acid and nonconjugated D-glucuronic acid. J Biol Chem (1957) 1.20
The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17
The biotransformation of ethyl biscoumacetate (tromexan) in man, rabbit and dog. J Pharmacol Exp Ther (1953) 1.08
[Interference of barbiturates in the action of tromexan]. Medicina (B Aires) (1955) 1.04
A simply prepared, standardized, and relatively stable thromboplastin extract for estimation of prothrombin time. Am Heart J (1950) 0.94
The effect of water-soluble preparations of vitamin K in dicumarol-induced hypoprothrombinemia. N Engl J Med (1950) 0.89
The control of prothrombin activity with tromexan therapy. Am J Med (1953) 0.85
The physiological disposition of ethyl biscoumacetate (tromexan) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1952) 0.84
Effect of starvation, acenocoumarin and vitamin K on the coagulation pattern of the guinea pig. Exp Med Surg (1959) 0.82
[The effect of barbiturate anesthetics on the blood coagulation system; thromboelastographic findings]. Acta Anaesthesiol (1956) 0.81
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 3.60
Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med (1959) 1.38
The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther (1963) 1.33
Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med (1954) 1.22
Occurrence of fibrinolytic activity following administration of incotinic acid. Proc Soc Exp Biol Med (1959) 1.18
The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17
A STUDY OF STRUCTURE--ACTIVITY RELATIONSHIPS IN REGARD TO SPECIES DIFFERENCE IN THE PHENYLBUTAZONE SERIES. Biochem Pharmacol (1964) 1.12
MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS. J Clin Invest (1963) 1.09
A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog. Am J Med (1960) 1.08
Biochemical pharmacological considerations of phenylbutazone and its analogues. Ann N Y Acad Sci (1960) 1.08
The biotransformation of ethyl biscoumacetate (tromexan) in man, rabbit and dog. J Pharmacol Exp Ther (1953) 1.08
Studies on the glucuronic acid pathway of glucose metabolism. J Biol Chem (1959) 1.06
Observations on the drug-induced synthesis of D-glucuronic, L-gulonic and L-ascorbic acids in rats. J Pharmacol Exp Ther (1960) 1.03
Relationship of platelet serotonin to disturbances of clotting and hemostasis. Circulation (1957) 1.02
An evaluation of a new anticoagulant, acenocoumarin (sintrom). Circulation (1956) 0.99
Production of steam volatile acids by bacteria-free Ascaris lumbricoides. J Infect Dis (1951) 0.99
Further observations on the metabolism of L-ascorbic acid in guinea pigs. J Biol Chem (1956) 0.97
Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione). Proc Soc Exp Biol Med (1955) 0.97
Metabolism of the chelating agent diethylenetriamine pentaacetic acid (C14DTPA) in man. Proc Soc Exp Biol Med (1962) 0.97
Metabolism of L-gulonolactone in rats via pentose formation. Biochim Biophys Acta (1957) 0.97
Observations on vitamin C activity of D-ascorbic acid. Proc Soc Exp Biol Med (1959) 0.95
A simply prepared, standardized, and relatively stable thromboplastin extract for estimation of prothrombin time. Am Heart J (1950) 0.94
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent. J Clin Invest (1956) 0.93
Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. Am J Med Sci (1954) 0.91
The effect of water-soluble preparations of vitamin K in dicumarol-induced hypoprothrombinemia. N Engl J Med (1950) 0.89
The influence of the physiologic disposition of chelates on their use in medicine. Ann N Y Acad Sci (1960) 0.88
Influence of some vasoactive drugs on fibrinolytic activity. Circulation (1959) 0.88
Metabolism of C14-labeled ascorbic, dehydroascorbic and diketoglulonic acids in guinea pigs. Arch Biochem Biophys (1959) 0.87
Metabolism of sulfinpyrazone (Anturane) and other thio analogues of phenylbutazone in man. J Pharmacol Exp Ther (1961) 0.87
THE FIBRINOLYTIC RESPONSE TO NICOTINIC ACID IN ABNORMAL LIVER STATES. Am J Med Sci (1963) 0.87
The control of prothrombin activity with tromexan therapy. Am J Med (1953) 0.85
The physiological disposition of ethyl biscoumacetate (tromexan) in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1952) 0.84
Effect of starvation, acenocoumarin and vitamin K on the coagulation pattern of the guinea pig. Exp Med Surg (1959) 0.82
Metabolism of L-ascorbic acid in rat kidney. J Biol Chem (1958) 0.82
The physiologic disposition of phenylindanedione in man. J Pharmacol Exp Ther (1954) 0.81
Passage of thiopental and barbital into ocular and cerebrospinal fluids of dog. Proc Soc Exp Biol Med (1961) 0.80
Residual serum thrombin activity. Clin Chem (1958) 0.78
Stimulus generalization as a function of verbal reinforcement combinations. J Exp Psychol (1954) 0.77
Studies of coagulation and fibrinolysis by new technic of continuous recording. Blood (1955) 0.76
Clot retraction and fibrinolysis. Clin Chem (1963) 0.75
Effects of training in space orientation on perception of the upright. J Exp Psychol (1955) 0.75
The dilution of plasma in estimating prothrombin activity. Acta Haematol (1950) 0.75
The vitamin K tolerance test. Am J Clin Pathol (1948) 0.75
DRUG-INDUCED INCREASE OF PROTHROMBIN COMPLEX ACTIVITY IN VIVO. Am J Med Sci (1964) 0.75
A p-nitro analogue of phenylbutazone possessing potent antirheumatic, sodium retaining and uricosuric properties. J Pharmacol Exp Ther (1959) 0.75
Dicumarol therapy. J Med Soc N J (1951) 0.75
Microclotting techniques. J Lab Clin Med (1960) 0.75
Ethyl butyrate hydrolyzing activity of human serum. Am J Clin Pathol (1950) 0.75
Physiological disposition of 2-phenyl quinoline-4-carboxylic acid (cinchophen) in man; method for its estimation in biological material. Proc Soc Exp Biol Med (1954) 0.75
Lability of fibrinolysin. Nature (1959) 0.75
Investigation of coagulation defects using a modified prothrombin consumption test. Bull N Y Acad Med (1952) 0.75
Parahemophilia; Owren's disease. Pediatrics (1953) 0.75
The diuretic action of a coumarin-mercurial compound. J Lab Clin Med (1950) 0.75
Influence of fibrinogen concentration upon plasma prothrombin time. Blood (1949) 0.75
Coumarin anticoagulant agents. Trans Am Coll Cardiol (1952) 0.75
A comparative study of effects of coumarines by the use of a microprothrombin method. Exp Med Surg (1952) 0.75
Clot firmness. Blood (1957) 0.75
Significance of clotting tests augmented by heparin. Am J Clin Pathol (1956) 0.75
Metabolism of D-ascorbic acid-1-C14 in guinea pigs and rats. J Biol Chem (1958) 0.75
Passage of barbital into cerebrospinal fluid. Proc Soc Exp Biol Med (1960) 0.75
FACTORS INFLUENCING THE CLINICAL USE OF CHELATES IN IRON STORAGE DISEASE. Ann N Y Acad Sci (1964) 0.75
Physiologic disposition and uricosuric effect of a keto analog of oxyphenbutazone (G-29701). Arthritis Rheum (1960) 0.75
The clinical response in arthritis of long standing. Med Times (1950) 0.75
STUDIES OF THE PROLONGED BIOCHEMICAL EFFECTS OF 3-METHYLCHOLANTHRENE AND OF ITS PHYSIOLOGICAL DISPOSITION IN THE RAT. Biochem Pharmacol (1964) 0.75
Transitory variations in serum prothrombin activity. Proc Soc Exp Biol Med (1952) 0.75
PROBLEMS OF COOLEY'S ANEMIA: PANEL DISCUSSION. Ann N Y Acad Sci (1964) 0.75
Fate of 2-keto-L-gulonic acid in rat and guinea pig. Proc Soc Exp Biol Med (1957) 0.75
THE SIGNIFICANCE OF THE PHYSIOLOGIC DISPOSITION OF DRUGS IN ANTICOAGULANT THERAPY. Semin Hematol (1964) 0.75
Afibrinogenemia occurring in a case of malignancy of the prostate with bone metastases. N Y State J Med (1949) 0.75
Fate of dicumarol in man; relationship between prothrombin time and plasma levels of dicumarol. Bull N Y Acad Med (1949) 0.75
Platelet adhesiveness. Blood (1948) 0.75
MODIFICATION OF METHOD OF ANALYSIS OF METHOHEXITAL IN HUMAN PLASMA. Anesthesiology (1964) 0.75
The effect of penicillin upon the coagulability of the blood. Exp Med Surg (1948) 0.75
Observations on bound ascorbic acid in guinea pig liver. Proc Soc Exp Biol Med (1956) 0.75
Hyperfibrinogenemia. Report of a case. JAMA (1962) 0.75
Nonspecific factors in blood coagulation. J Lab Clin Med (1955) 0.75
The response of hypoprothrombinemia in cirrhosis to vitamin K1 and K3. Am J Med Sci (1961) 0.75
Lack of effect of coenzyme Q10 on coumarin-induced hypoprothrombinaemia. Nature (1961) 0.75
Estimation of prothrombin time. J Am Med Assoc (1948) 0.75
The perpetual chain around the neck of the Jew-his own self. Am Imago (1953) 0.75
The effects of differently structured visual fields on the perception of verticality. Am J Psychol (1955) 0.75
Effect of environmental temperature upon clotting time of whole blood. Proc Soc Exp Biol Med (1948) 0.75
An evaluation of methods of dicumarol administration. Am Heart J (1951) 0.75
Ascorbic acid and blood coagulation. Ann N Y Acad Sci (1961) 0.75